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1061-86 Underutilization of Oral Anticoagulation for Atrial 
Fibrillation in Survivors of Acute Myocardial Infarction 
Influences Long-Term Mortality
Ulf Stenestrand, Lars Wallentin, Heart Center, University Hospital, Linkoping, Sweden, 
UCR, University Hospital, Uppsala, Sweden
Background: Oral anticoagulation (OAC) treatment is generally recommended in
patients with atrial fibrillation (AF) and coronary artery disease. We investigated the pre-
scription of OAC in patients discharged alive with atrial fibrillation after an acute myocar-
dial infarction (AMI) and the influence of OAC treatment on 1-year mortality.
Methods: Prospective cohort study using data from the Register of Information and
Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) on patients
admitted to the coronary care units of 72 Swedish hospitals 1995-2001. All 11141
patients with first registry-recorded AMI who were discharged with atrial fibrillation were
included. 1-year mortality data were obtained from the Swedish National Cause of Death
Register.
Results: Only 21 %(n=2384) of the patient were prescribed OAC while 79% (n=8757)
were not. At 1 year unadjusted mortality was 26% (2301 deaths) in the no-OAC group
and 20% (481 deaths) in the OAC treated group. Also in Cox regression analysis adjust-
ing for 36 confounding factors OAC treatment was associated with reduction in 1-year
mortality (relative risk, 0.66; 95% confidence interval 0.57-0.76; P<0.001) in hospital sur-
vivors of AMI with AF. This reduction of mortality was similar among all subgroups based
on age, sex, baseline characteristics, previous disease manifestations, and medications. 
Conclusions: In daily clinical practise OAC is only given to a minority (21%) of AMI
patients with AF despite that OAC is associated with a 34% relative reduction in 1-year
mortality. The results emphasizes the importance of OAC treatment for AF after AMI.
1061-87 Effects of Zofenopril on Ischemia Following Myocardial 
Infarction: The SMILE Study
Claudio Borghi, Ettore Ambrosioni, St. Orsola-Malpighi Hospital, Bologna, Italy
Background. Zofenopril calcium is an ACE-inhibitor with a SH-moiety which showed to be
effective in pts with MI. Aim of study was to investigate anti-ischemic effects of zofenopril
(Z) in post-MI pts with normal LV function.
Methods. A multicentre, randomized, double-blind, placebo-controlled study was per-
formed in 349 post-MI pts with LV ejection fraction (LVEF) > 40% treated with Z (30-60
mg/day) or placebo in addiction to recommended therapy for a period of 6 months. Pri-
mary objective was 6-month combined occurrence of: new onset of significant ECG
abnormalities, ST-T abnormalities during 48-hour ambulatory ECG monitoring, recurrent-
MI, need of revascularization procedures for angina. Secondary objectives were 6-month
mortality and morbidity, new onset of post-MI angina, clinical and ECG response to exer-
cise test, rate of CHF (NYHA class II-IV).
Results. One hundred seventy-seven pts have been randomly allocated to Z and 172 to
placebo. Fifteen pts have been excluded from analysis because of protocol violation or
lost at follow-up. At baseline the two populations were comparable for demographic pro-
file, prevalence of cardiovascular risk factors, MI size and location, LVEF (54.4+/- vs
53.3+/-9), BP and concomitant drug therapy. ST depression on ambulatory ECG
occurred in 10.7% of Z treated pts and in 22.2% of those taking placebo (2p=0.027).
Peak ST depression was 1.57 mm vs 2.57 mm in pts treated with Z and placebo respec-
tively (2p=0.038). Mean duration of ST depression in the same populations was 7.6 min
and 25.2 min (2p=0.020). In response to exercise test a lesser proportion of patients
treated with Z complained anginal pain (4.7 vs 14.3%; 2p=0.017), significant ST depres-
sion (14.2 vs 26.7%; 2p=0.024) and relevant arrhythmias (3.8 vs 10.5%; p=0.048). Time
to ST depression during exercise was increased (6.93 vs 4.42 min; 2p=0.024) and peak
ST depression (1.21 vs 1.95 mm; p=0.001) was reduced in Z treated patient. Major car-
diovascular events were evenly distributed between study populations with a lesser rate
of progression of CHF in Z pts.
Conclusions. This randomized, placebo controlled clinical trial support the anti-ischemic
role of Z when given to pts with normal LV function following acute MI.
1061-88 Causes of Death in Patients With ST Elevation 
Myocardial Infarction Treated With Fibrinolysis
Amir Kashani, Elliott M. Antman, David A. Morrow, Robert P. Giugliano, TIMI-Study 
Group; Brigham & Women's Hospital, Boston, MA, Rochester General Hospital, 
Rochester, NY
Background: Recent developments in reperfusion pharmacologic therapy have not fur-
ther reduced mortality in ST-Elevation myocardial infarction (ST-EMI). We explored the
causes of death in a recent ST-EMI megatrial to better understand why patients die fol-
lowing fibrinolysis.
Methods: We evaluated the investigator reported causes of death in 15,078 patients
enrolled in InTIME-II (lanoteplase vs alteplase).
Results: There were 913 deaths (6.1% mortality) during the index hospitalization, 93
deaths (0.7% mortality) between hospital discharge and 30 days, and 303 deaths (2.2%
mortality) between 31 and 180 days. The six leading causes of early (< 30 days) death
(n=1006 deaths, 6.7% mortality) were congestive heart failure (CHF) (30%), recurrent MI
(20%), cardiac rupture (17%), intracranial hemorrhage (9%), other cardiovascular (9%),
and dysrhythmia (7%). Between 30 days and 6 months the leading causes of death were
recurrent MI (20%), other non-cardiac (20%), and CHF (18%). Among patients with
shock or severe CHF (n=1801, 11.9% incidence) during the index admission, CHF
accounted for 53% of the early deaths.
Conclusions: In the modern fibrinolytic era, 30% of early deaths are due to CHF. Among
patients developing early shock or severe heart failure, CHF accounted for more than half
of the deaths through 30 days. These findings suggest that attempts to reduce early mor-
tality after fibrinolysis should include both therapies that improve myocardial salvage, and
more aggressive treatment of post-MI CHF.
1061-89 Trends in Non-ST-Segment Elevation Myocardial 
Infarction Care: The National Acute Myocardial 
Infarction Project 1998-2001
JoAnne M. Foody, Deron H. Galusha, Saif S. Rathore, Frederick A. Masoudi, Edward P. 
Havranek, Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT
Background: In 2000, the ACC/AHA published guidelines for patients with NSTEMI.
Whether release of these guidelines has been associated with increasing use of evi-
dence-based therapies is unknown.
Methods: In two national cohorts of 31,399 and 31,759 older patients hospitalized
between 1998-9 and 2000-1 respectively with confirmed AMI, we identified patients who
presented with NSTEMI (n=19,278 in 1998-9 and n=21,007 in 2000-1). We assessed
change in quality of care using 6 quality of care indicators: admission use of aspirin,
admission use of beta blockers, discharge prescription of aspirin, discharge prescription
of beta blockers, ACE inhibitors and lipid lowering in ‘ideal candidates’ without treatment
specific contraindications.
Results: An increasing proportion of older patients admitted with AMI had NSTEMI
(61.4% in 1998- 9 and 66.6% in 2000-1). From 1998-9 to 2000-1, increases were seen in
admission use of aspirin and beta-blockers as well as discharge prescription of aspirin,
beta blockers, ACE Inhibitors and lipid lowering therapy.
Conclusions: Two thirds of Medicare beneficiaries hospitalized with AMI in 2000-1 pre-
sented with NSTEMI. Only modest advances were made nationally in the care of older
patients with NSTEMI and a significant proportion of patients with NSTEMI do not
receive evidence-based care. Further interventions are required to improve care for the
growing numbers of patients presenting with NSTEMI.
1061-90 Effects of Mechanical Left Ventricular Unloading on 
Endothelin-1 Release and Apoptosis
Hela C. Achour, Fernando Boccalandro, Maximilian L. Buja, Yong-Jian Geng, James 
Amirian, Patty Felli, Richard W. Smalling, University of Texas Health Science Center, 
Houston, TX
Background: Endothelin-1 (ET) and apoptosis may play a pivotal role in mediating tis-
sue injury during myocardial ischemia and reperfusion. Left ventricular (LV) unloading
during myocardial infarction has been shown to limit reperfusion injury and infarct size.
The purpose of this study was to determine the prevention of or reversibility of these pro-
cesses under mechanical LV assistance.
Methods: Six dogs subjected to 2 hours of left anterior descending coronary artery
(LAD) occlusion followed by 4 hours of reperfusion were randomly assigned to: 1/ a con-
trol group (n= 3) with sham LV assistance on, 2/ a treated group (n= 3) with mechanical
LV assistance on, using a trans-valvular LV assist device, initiated 10 minutes prior to
reperfusion. Serial ET levels were obtained from the coronary sinus and aortic blood and
measured by radio-immunoassay. The extent of contraction band necrosis in the
ischemic area defined by Evan's blue dye was determined by quantitative histology. Car-
diomyocyte apoptosis was determined by terminal deoxynucleotidyl transferase-medi-
ated dUTP nick-end labeling (TUNEL) staining.
Results: A similar increase in aortic and coronary sinus blood ET was observed in both
groups during LAD occlusion. A significant trans-cardiac increase in ET levels was
present in the control group 10 minutes after reperfusion whereas no increase occurred
Causes of Death
Variable Inhospital Death 30 Days Death 31-180 Days Death
(N=913) (N=1006) (N=303)
CHF 30.0 29.6 17.5
Recurrent MI 20.2 20.2 19.8
Rupture 18.5 16.9 0.3
Intracranial Hemorrhage 10.0 9.0 0.7
Other Cardiovascular 8.8 8.7 8.3
Dysrhythmia 6.6 6.9 8.6
Other Non-Cardiac 3.5 3.9 19.8
Unobserved 1.3 3.1 9.9
Unknown 1.2 1.7 15.2
Numbers in table represent percentages of death.
Trends In AMI Care
1998-1999 Rate
(%)
2000-2001 Rate
(%)
Early aspirin 81.9 84.0
Discharge aspirin 84.0 85.5
Early beta blocker 60.6 66.8
Discharge Beta blocker 70.6 77.8
Discharge ACE inhibitor 66.6 72.9
Discharge Lipid lowering 52.1 69.4
264A ABSTRACTS - Myocardial Ischemia and Infarction JACC March 3, 2004
M
yo
ca
rd
ia
l I
sc
he
m
ia
 a
nd
 In
fa
rc
tio
n
in the unloaded animals (202.17 ± 49.89 pg/100µl vs 15.29 ± 8.45 pg/100 µl respec-
tively). Greater contraction band necrosis with edema and interstitial hemorrhage was
observed in the ischemic and infarct regions of the control dogs compared to the
unloaded animals. In the central ischemic region of the treated animals, we counted an
average of 410 nuclei; 22.81 ± 6.4 % displayed TUNEL-positive staining. In contrast, for
the same amount of nuclei counted 35.18 ± 5.17% displayed TUNEL-positive staining in
the ischemic region of the control animals.
Conclusions: Mechanical LV unloading, just prior to reperfusion reduces coronary sinus
plasma ET-1 levels immediately after reperfusion and limits the extent of contraction band
necrosis and the loss of cardiomyocytes through apoptosis in the central ischemic region
in a canine ischemia-reperfusion model.
1061-91 Randomized Comparison of Prehospital Combination 
Fibrinolysis Versus Prehospital-Initiated Facilitated 
Percutaneous Coronary Intervention in Acute 
Myocardial Infarction
Holger Thiele, Lothar Engelmann, Kathleen Elsner, Wulf-Hinrich Storch, Rahimi Kazem, 
Andreas Hartmann, Dietrich Pfeiffer, Wolfgang Rothe, Enno Boudriot, Gerhard Schuler, 
University of Leipzig - Heart Center, Leipzig, Germany
Background: Prognosis in acute myocardial infarction (AMI) is mainly determined by
early reperfusion and restoration of a normal flow in the infarct related artery. However,
reperfusion therapy for AMI with thrombolysis has been shown to achieve a 50-60%
TIMI-3-flow only. Early trials combining thrombolysis and PTCA have failed to show a
mortality benefit mainly as a cause of encountered bleeding complications. New pharma-
cological developments might allow a facilitated PCI approach initiated in the prehospital
setting.
Methods: Since 12/2000 151 patients with an AMI were randomized within 6 hours after
symptom onset to either a prehospital COMBO (half dose Reteplase + abciximab) with
in-hospital conservative therapy (n=75) or a prehospital initiated COMBO therapy with
immediate in-hospital "facilitated" PCI (n=76). Primary endpoints were ST-segment reso-
lution at 90 min., infarct size expressed as area under the curve of CK-release and as
delayed enhancement MRI. The secondary endpoint was a composite of mortality, re-
AMI, major bleeding and stroke.
Results: Mean time from symptom onset to arrival of the emergency physician was 109±
80 min. in COMBO only in comparison to 106± 40 min. in the facilitated PCI-group
(p=n.s.). In the facilitated PCI-group TIMI-3-flow before intervention was 65% and after
96%, respectively. 90-min ST-segment resolution was more complete in the facilitated
PCI group (57± 48% vs. 83± 23%, p<0.001). Infarct size measured by CK-release was
873± 854 in the COMBO only versus 617± 400 µ mol/l/h in the facilitated PCI-group
(p=0.02) and 12± 11% versus 7± 6% of the left ventricular mass in the delayed enhance-
ment MRI (p=0.005). In the secondary combined endpoint there was a trend towards a
lower event rate in the facilitated PCI group. (31% vs. 20%, p=0.18).
Conclusion: "Facilitated" PCI after prehospital initiated combination thrombolysis results
in a an improved tissue perfusion as shown by the ST-segment resolution, which leads to
smaller infarct sizes. As a consequence there is a trend towards a lower clinical event
rate.
1061-92 Relation Between Time of Pain and Long-Term Outcome 
in Patients With Acute Myocardial Infarction Transferred 
to Primary Angioplasty or Angioplasty Facilitated With 
Thrombolysis
Mariusz Gasior, Marek Gierlotka, Andrzej Lekston, Tadeusz Zebik, Krzysztof Wilczek, 
Janusz Szkodzinski, Marek Kondys, Jacek Piegza, Jaroslaw Wasilewski, Krzysztof 
Dyrbus, Bozena Szygula-Jurkiewicz, Lech Polonski, Silesian Centre for Heart Disease, 
Zabrze, Poland, Medical University of Silesia, Zabrze, Poland
Background: It is unknown whether thrombolytic administration before angioplasty (PCI)
for acute myocardial infarction (AMI) is superior to primary PCI. The aim of the study was
to evaluate the relationship between symptom-onset-to-PCI time and 2-year outcome in
patients (pts) transferred to primary PCI or PCI facilitated with thrombolysis.
Methods: A total of 368 consecutive pts (cardiogenic shock pts excluded) were included
in the analysis. Thrombolysis was administered in the referral hospitals in 180 (49%) of
pts when the anticipated time to PCI exceeded 60 minutes.
Results: In primary PCI, symptom-onset-to-PCI time was negatively associated with left
ventricle ejection fraction (p = 0.013), but was not in facilitated PCI. Two-year incidence of
death, myocardial infarction or stroke (MACE) in relation to symptom-onset-to-PCI time is
shown in the figure. At multivariate analysis, administration of thrombolytic in patients
with symptom-onset-to-PCI time <= 4 h was an independent predictor of MACE (relative
risk = 2.55; 95% confidence interval = 1.16-5.63). Oppositely, in patients with symptom-
onset-to-PCI time > 4 h, thrombolysis was associated with good prognosis (relative risk
of MACE = 0.45; 95% confidence interval = 0.22-0.91).
Conclusion: This study supports the idea of thrombolytic treatment before angioplasty
but only in patients with PCI performed after 4 hours of pain. Utilization of thrombolysis
before PCI performed up to 4 hours from the onset of AMI could worsen the outcome.
1061-93 Granulocyte-Colony Stimulating Factor Induced 
Mobilization and Intra-Coronary Infusion of Mobilized 
Whole Leukocyte Is a Feasible, Safe Method of Stem 
Cell Transplantation in Patients With Myocardial 
Infarction
Hyun-Jae Kang, Hyo-Soo Kim, Hyun-Jai Cho, Bon-kuen Koo, Yong-Jin Kim, Dae-Won 
Sohn, Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-Shik Choi, Seoul 
National University College of Medicine, Seoul, South Korea, Seoul National University 
Hospital, Seoul, South Korea
Background: Beneficial effects of bone marrow stem cell transplantation in patients with
MI brought the need of noninvasive stem cell mobilization. Safety and feasibility of G-
CSF induced stem cell mobilization and mobilized cell infusion is unknown. We tested the
clinical feasibility and effects of G-CSF induced mobilization and intra-coronary infusion
in patients with MI.
Methods: We randomly allocated 22 patients (56 ± 11years old, LVEF =50 ± 12%) into
three groups: 1) G-CSF group: G-CSF induced mobilization (n= 10, 6 AMI patients), 2)
Infusion group: intra-coronary infusion of G-CSF mobilized cells (n = 10, 4 AMI patients),
3) Non-mobilization group (n=2, 2 AMI patients). G-CSF with 10ug/kg/day for 4.2 ± 0.7
days were administrated to G-CSF and infusion group. And then all groups underwent
percutaneous coronary intervention (PCI) for culprit lesion. MIBI SPECT and PET were
performed before PCI and treadmill test and dobutamine stress echo were performed
after PCI. Follow up coronary angiography and noninvasive studies were performed after
6 months later.
Results: Patients in each study group showed no significant differences in baseline char-
acteristics. No adverse reaction was observed except mild headache (3 patients) with G-
CSF administration. Patients in infusion group underwent apheresis before PCI and 1.5 ±
0.5 x 109 leukocytes (7.6 ± 2.9 x 107 CD 34+ cells) were infused after PCI without compli-
cation. Elevation of CK-MB after PCI were comparable among study groups (Before and
12hours after PCI, Infusion group: 2.2 ± 2.2 vs. G-CSF group: 0.3 ± 3.1 vs. Non-mobiliza-
tion group: 1.5 ± 0.7U/L, p=0.34). Symptom and ECG had not changed after PCI. No
reflow phenomenon was not observed and coronary flow reserve did not worsened with
cell infusion (before and 10minutes after infusion: 1.7 ± 0.4 vs. 1.7 ± 0.5: p=0.75). Three
symptomatic restenosis(one from cell infusion group and two from G-CSF group) were
observed during mean 4 ± 1month clinical follow up.
Conclusions: G-CSF is a feasible and safe stem cell mobilizer in MI. Apheresis and whole
leukocyte infusion after G-CSF mobilization is a practical method of stem cell transplan-
tation.
1061-94 Recovery of Left Ventricular Function by Carvedilol Is 
Associated With Concomitant Increase of Myocardial 
Perfusion in Patients With Acute Myocardial Infarction
Shinichiro Yamada, Kenji Fujii, Akira Takarada, Takatatoshi Hayashi, Yoshihiro Ikeda, 
Kohei Yamashiro, Kazuo Mizutani, Teishi Kajiya, Himeji Cardiovascular Center, Himeji, 
Japan
Background: Recent studies have shown that carvedilol reduces all-cause mortality in
patients with left ventricular dysfunction after acute myocardial infarction (AMI). However,
the mechanisms remain unknown. We serially studied the effects of carvedilol on both
Left ventricular function and myocardial perfusion after AMI. Method: Seventy-eight
patients (61.3±9.6 years, 64 males) who underwent successful percutaneous coronary
intervention for AMI were recruited to this study. They were divided into two groups:
carvedilol (5-20 mg, daily) group (N=39) and infarct-related artery matched control group
(N=39). Tc-99m tetrofosmin ECG-gated SPECT imaging (TF) was performed 7-10 days
after the onset (baseline). Left ventricular ejection fraction (LVEF) was obtained from TF
using automated quantitative method. The myocardium was divided into 17 segments for
analysis of regional perfusion and segmental score was graded by 5 degrees according
to the relative activity against normal perfusion segment (0: normal, 4: defect). Follow-up
TF study was performed 3 months (chronic) after onset to identify the improvements of
LVEF and myocardial perfusion. Result: Baseline characteristics (carvedilol group versus
control group; age: 61.8±10.4 years versus 60.9±8.9 years, peak CPK: 4475±2629 IU/l
versus 4084±2186 IU/l) were similar in both groups. In baseline TF, LVEF (carvedilol
group 43.3% versus control group 46.4%), the total of defect scores (TDS) (19.6 ±9.3
versus 16.6±6.8) and the number of hypo-perfusion (score grade >1) segments (HS)
(10.2±3.0 versus 9.4±2.6) did not differ significantly. However, in chronic TF, improvement
of LVEF from baseline is significantly greater in carvedilol group than that in control group
(carvedilol group +7.6% versus control group +0.4%, p=0.0004). Moreover, TDS and HS
were significantly decreased from baseline in only carvedilol group (TDS: carvedilol
group -2.8 Versus control group +1.1, p=0.001, HS: -1.2 Versus +0.4, p=0.004). Conclu-
sion: Carvedilol after primary percutaneous coronary intervention improves myocardial
perfusion and left ventricular function in AMI. This result may explain the beneficial effect
of carvedilol treatment.
